Chief Executive Officer Emma Walmsley is embarking on a long-planned transformation of the drugmaker that includes spinning off Glaxo's consumer health unit, paring the dividend and increasing the number of promising treatments in development. Walmsley and her executives set out details of the strategy for the first time last week.